News

Caris Life Sciences to Present Key Research Findings on its Molecular Intelligence Platform at the 2017 ASCO Annual Meeting

Presentations Demonstrate Utility of Tumor Profiling to Guide Individualized Treatment IRVING, Tex., May 24, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the acceptance of 11 abstracts, including an oral abstract session, two poster discussion sessions and eight poster sessions, by the … Continued

Caris Life Sciences Appoints John Marshall, M.D., as Chief Medical Officer

IRVING, Texas, May 17, 2017 – Caris Life Sciences, a leading innovator in molecular science, today announced the appointment of John Marshall, M.D., as its Chief Medical Officer. Dr. Marshall will direct the company’s oncology research efforts via the Caris Research Institute™ and guide clinical strategies for innovative precision medicine tools and tumor profiling services, … Continued

Caris Life Sciences’ ADAPT Biotargeting System Identifies a Key Cell Surface Regulator of MYC as the Molecular Target of a Cytotoxic Aptamer

Study Data Presented at AACR 2017 Annual Meeting Demonstrates the Ability of ADAPT Biotargeting System to Identify Molecular Targets for Anti-cancer Aptamers  IRVING, Texas, Apr. 3, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced results of a study that demonstrate the ability … Continued

Caris Life Sciences’ Results Demonstrate Ability of ADAPT Biotargeting System to Detect Breast Cancer Subtypes from Liquid Biopsy Samples

Enriched Aptamer Libraries Identified 100% of Patients with ER+/PR+/HER2- Lobular Carcinoma Breast Cancer in Pilot Study Presented at AACR 2017 Annual Meeting IRVING, Texas, Apr. 3, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced results of a study that demonstrate the ability … Continued

Caris Life Sciences Announces Presentations at AACR 2017 Annual Meeting Demonstrating the Broad Capabilities of ADAPT Biotargeting System

  Caris’ Novel Profiling Platform Facilitates a Deeper Understanding of Molecular Complexes to Support Drug Development and Advance Precision Medicine IRVING, Texas, Mar. 21, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced four abstracts that will be presented at the American Association … Continued

New Data in Nature’s Scientific Reports Shows Caris Life Sciences’ ADAPT Platform Detects Breast Cancer in Women via Liquid Biopsy of Circulating Exosomes

  Results Demonstrate Potential of Unprecedented Technology Approach to Classify Women Regardless of Breast Density IRVING, Texas, Feb. 21, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the results of a study that demonstrates the ability of the company’s ADAPT Biotargeting System™ … Continued

Caris Life Sciences and the Lustgarten Foundation Collaborate to Support Immunotherapy Clinical Trial for Pancreatic Cancer

Leveraging Precision Medicine to Evaluate Immunotherapy Opportunities for the Most Lethal Form of Cancer IRVING, Texas, Jan. 18, 2017 – Caris Life Sciences, a leading innovator in molecular science, and the Lustgarten Foundation, the largest private funder of pancreatic cancer research, are collaborating to support a clinical trial evaluating the impact of immunotherapy in the treatment … Continued

Caris Life Sciences Designates West Virginia University Cancer Institute a Caris Center of Excellence for Precision Medicine

West Virginia University Joins Precision Medicine Network to Broaden Access and Advance Clinical Utility of Tumor Profiling  IRVING, Texas, Nov. 3, 2016 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the designation of the West Virginia University (WVU) Cancer Institute as a center of excellence site … Continued

Caris Life Sciences and Threshold Pharmaceuticals Collaborate to Utilize Caris’ ADAPT Biotargeting System in the Development Program for Evofosfamide

Caris Life Sciences to Develop a Customized Assay for Pancreatic Cancer Patients to Predict Likelihood of Response to Evofosfamide, Threshold Pharmaceutical’s Lead Drug Product Candidate IRVING, Texas and SOUTH SAN FRANCISCO, Calif., Oct. 25, 2016 – Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, and Threshold Pharmaceuticals, Inc. … Continued

1 2 3 14

About Our News

Search to find the latest new about Caris Molecular Intelligence®, sign up for news alerts, and be sure to follow us on social media.